Letter by Sarayani et al Regarding Article, "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque"

Circulation. 2021 Jun 22;143(25):e1031-e1032. doi: 10.1161/CIRCULATIONAHA.120.052678. Epub 2021 Jun 21.

Authors

Amir Sarayani¹, Sebastian Jugl¹, Almut G Winterstein¹

Affiliation

¹ Center for Drug Evaluation and Safety and Department of Pharmaceutical Outcome and Policy, College of Pharmacy, University of Florida, Gainesville.

PMID: 34152796
DOI: 10.1161/CIRCULATIONAHA.120.052678

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Comment

MeSH terms

Cardiovascular Diseases* / chemically induced
Cardiovascular Diseases* / epidemiology
Humans
Immune Checkpoint Inhibitors
Plaque, Atherosclerotic*

Substances

Immune Checkpoint Inhibitors